Key Takeaways
- Veeva Systems stock currently hovers around $285, with Wall Street projecting potential gains exceeding 30% within the coming year.
- The firm is transitioning its largest clients away from Salesforce infrastructure to its proprietary Veeva Vault CRM solution, securing commitments from 14 of the world’s top 20 biopharmaceutical companies.
- Second-quarter fiscal results showed revenue climbing to $928 million, marking an 18% year-over-year increase, prompting management to lift full-year projections to approximately $3.7 billion.
- The newly launched Falcon platform leverages agentic AI capabilities to streamline medical and regulatory workflows, potentially reducing manual labor by as much as 70%.
- French pharmaceutical giant Servier is implementing Veeva OpenData across over 80 markets to establish a globally unified, AI-optimized data infrastructure.
Shares of Veeva Systems settled at $285.45 on September 30, 2026. While this represents a significant decline from the company’s 2021 peak of $344, several Wall Street analysts believe the stock has substantial upside potential ahead.
The enterprise specializes in developing software solutions tailored for pharmaceutical and biotechnology organizations. Its offerings span clinical trial management, regulatory submission processes, and commercial sales operations.
With an impressive market share exceeding 80% in the biopharma customer-relationship management sector, Veeva commands a powerful foothold in a specialized industry segment that rarely makes headlines.
Breaking Free from Salesforce Dependency
Historically, Veeva’s platform operated on Salesforce infrastructure. Beginning in 2024, the company initiated development of its proprietary alternative, Vault CRM, and started transitioning existing customers.
This strategic pivot provides Veeva with improved profit margins and complete oversight of its technology stack. Importantly, it eliminates reliance on a rival company’s foundation.
To date, 14 of the planet’s 20 largest biopharmaceutical enterprises have pledged to adopt Vault CRM. This widespread commitment demonstrates the transition is gaining meaningful traction.
Wells Fargo’s Stan Berenshteyn maintains an Overweight rating on the stock with a $330 price objective. He highlights fresh CRM contract wins and expanding momentum in Veeva’s data cloud offerings as catalysts worth monitoring.
Embracing Agentic AI Technology
Veeva’s latest innovation is the Falcon platform, engineered to execute complex, multi-stage processes with minimal human intervention.
A current application is Falcon MLR, which automatically evaluates promotional content for medical, legal, and regulatory adherence. Additional agents targeting clinical operations, regulatory affairs, and pharmacovigilance are scheduled for release throughout 2027.
According to Veeva’s projections, these automation capabilities could eliminate up to 70% of certain repetitive tasks. The company further suggests that drug development cycles might accelerate by 30% to 90% when utilizing its technology suite.
Gartner forecasts that worldwide investment in task-oriented AI agents will more than double annually through 2029, representing a 119% compound annual growth rate and surpassing $750 billion in total spending.
Veeva’s fiscal second-quarter performance delivered revenue of $928 million, representing an 18% year-over-year improvement. Adjusted earnings per share reached $2.35, matching the revenue growth percentage.
Management elevated its full-year revenue forecast to approximately $3.7 billion, marking the third such increase within the current fiscal period.
Adjusted earnings per share guidance for the full year now approaches $9.21, reflecting a 14% advance from the prior year. Leadership has established an ambitious target of achieving a $6 billion annual revenue run rate by 2030.
Reaching this milestone would require maintaining an average annual expansion rate near 18% across the next three years. The objective was initially established in 2023, predicated on anticipated market share expansion across Veeva’s flagship product lines.
The equity currently trades at roughly 27 times forward earnings projections. While this valuation exceeds both the broader market and Salesforce’s 14 times multiple, it remains below Veeva’s own five-year historical average of 35 times.
Veeva consistently maintains operating margins above 45%. When combined with revenue growth approaching 15%, the company comfortably exceeds the software industry’s widely recognized “Rule of 40” performance threshold.
The firm maintains a debt-free balance sheet. Potential headwinds include execution challenges during the ongoing Salesforce migration and broader market volatility surrounding AI-focused equities.
On September 30, Veeva revealed that Servier, a major French pharmaceutical corporation, is deploying Veeva OpenData on a worldwide basis. Servier intends to harmonize customer reference information across more than 80 countries, creating what the company describes as an AI-ready data architecture.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
